Entities / Company
Agenus.
biotechnology company
- Reports this week
- 0
- Active events
- 0
- Connections
- 45
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
Gone quiet
No new reports in 90+ days-
Agenus, led by CEO Garo H. Armen, is a significant stakeholder in MiNK Therapeutics.Well supported4 reports
-
Illumina and Agenus were noted to operate within the same industry.Some support1 report
-
On July 14, 2025, Agenus was noted as one of 986 individual stocks in the Medical sector, outperforming while CVS Health also showed gains.Some support2 reports
-
Agenus presented clinical study data on botensilimab and balstilimab at the ESMO Congress in Berlin on July 26, 2025.Some support1 report
-
Agenus and Zydus Cadila announced on August 11, 2025, that they are collaborating on immunotherapy using botensilimab (BOT) and balstilimab (BAL).Some support2 reports
-
Agenus shares added 75.2% on August 12, 2025, significantly outpacing the S&P 500's 8.6% gain.Some support1 report
-
Richard Goldberg joined Agenus as Chief Development Officer, and Robin Taylor was appointed Chief Commercial Officer in September 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Agenus this week
News at the entities that move Agenus most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Agenus
-
Securities and Exchange Commission StructuralBlackRock, the manager of the iShares Core MSCI EAFE ETF, has made required filings with the Securities and Exchange Commission regarding institutional holdings.Moves Agenus
-
Renaissance Technologies TransactionalRenaissance Technologies holds a significant stake in Lite Strategy, Inc., whose stock trades on the Nasdaq exchange.Moves Agenus
-
CVS Health Mentioned togetherCVS Health and Aetna are facing regulatory scrutiny in Tennessee as the state considers restricting major health insurers.Moves Agenus
Connections
The 8 strongest of 45, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Richard Goldberg Structural
Richard Goldberg is employed as the Chief Development Officer at Agenus.
-
MiNK Therapeutics (United States) Structural
Agenus holds a 55% ownership stake in MiNK Therapeutics.
-
Garo H. Armen Structural
Garo H. Armen holds the roles of Founder, Chairman, and CEO of Agenus.
-
Zydus Cadila Structural
Agenus and Zydus Cadila maintain a strategic partnership involving manufacturing asset provision, licensing, and clinical development collaboration.
-
FDA Structural
The FDA regulates Agenus, influencing its operational policies and reviewing its data submissions.
-
Renaissance Technologies Transactional
Renaissance Technologies reduced its investment stake in Agenus.
-
Securities and Exchange Commission Structural
Agenus is subject to formal regulatory oversight and filing requirements mandated by the Securities and Exchange Commission.
-
CVS Health Mentioned together
Both companies are co-mentioned as strong performers within the medical sector.
History
Events by the month they beganAugust 2026
1 eventJune 2026
7 events- Agenus, led by CEO Garo H. Armen, is a significant stakeholder in MiNK Therapeutics.
- Illumina and Agenus were noted to operate within the same industry.
- On July 14, 2025, Agenus was noted as one of 986 individual stocks in the Medical sector, outperforming while CVS Health also showed gains.
- Agenus presented clinical study data on botensilimab and balstilimab at the ESMO Congress in Berlin on July 26, 2025.
- Agenus and Zydus Cadila announced on August 11, 2025, that they are collaborating on immunotherapy using botensilimab (BOT) and balstilimab (BAL).
- Agenus shares added 75.2% on August 12, 2025, significantly outpacing the S&P 500's 8.6% gain.
- Richard Goldberg joined Agenus as Chief Development Officer, and Robin Taylor was appointed Chief Commercial Officer in September 2025.